Yuhan Corporation Terminates Contract with I'mNeuron for Three New Brain Disease Drug Substances
[Asia Economy Reporter Lee Jung-yoon] Yuhan Corporation announced on the 8th that it has terminated the technology transfer and joint research and development contract for three new drug candidates for brain diseases signed with I'mNeuron Bioscience on February 19, 2020.
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
Additionally, I'mNeuron Bioscience has no obligation to return the contract payment of 1.2 billion KRW received from Yuhan Corporation, and Yuhan Corporation has no obligation to pay additional royalties to I'mNeuron Bioscience, the company announced.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
